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1089including 75,484 patients concluded that both
early and late stent thrombosis were higher in
the biodegradable polymer groups over second-
generation DES. These ﬁndings may partially explain
the higher rate of myocardial infarction in the
6-weeks DAPT group (5).
Given the unequivocal nature of the current data,
it is important to understand these individual
endpoints on a stent level. Whereas a strategy of a
shorter duration of DAPT may be reasonable in
second-generation DES, a longer duration of DAPT
will likely be needed in the bioabsorbable/degradable
stent platforms.*Femi Philip, MD
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2014;35:1147–58.REPLY: Duration of Triple Therapy in
Patients Requiring Oral Anticoagulation
After Drug-Eluting Stent ImplantationWe appreciate the comments of Dr. Philip regarding
the results of our ISAR-TRIPLE (Duration of Triple
Therapy in Patients Requiring Oral Anticoagulation
After Drug-Eluting Stent Implantation) trial (1). We
could not ﬁnd a signiﬁcant difference in clinical
outcomes between a 6-week and a 6-month triple
therapy duration in patients who received drug-
eluting stents (DES) and had an indication for
oral anticoagulation. Dr. Philip is concerned that a
shorter triple therapy might not apply to biodegradablepolymer (BP)-based DES (BP-DES) or fully bioresorbable
DES. In Dr. Philip’s opinion, on the basis of the results
of 2 network meta-analyses, BP-DES, when compared
with second-generation DES, are associated with an
increased risk for stent thrombosis and/or myocardial
infarction and, consequently, may need a longer
therapy duration. Our study certainly lacks the
power to look at differential treatment effects in
subgroups deﬁned by the type of DES used.
However, 3 of the 6 cases that incurred myocardial
infarction in the 6-week therapy group had received
new-generation everolimus-eluting stents (EES). In
total, there was no signiﬁcant interaction between
the use of BP-DES or EES and duration of triple
therapy regarding ischemic events. Moreover, with
only 6 patients (7 lesions) with fully bioresorbable
stents, we cannot make any statement about the
optimal triple therapy duration for this particular
device.
We would also like to highlight 3 more points.
First, categorization of DES into ﬁrst- and second-
generation or biodegradable polymer and permanent
polymer groups does not necessarily mean that the
devices included in each of these categories are
equally safe and effective. We have previously shown
that BP-DES with limited representation in the 2
meta-analyses cited by Dr. Philip show superior re-
sults to sirolimus-eluting stents at 4 years (2) and
equivalent results to EES at 5 years (3). Second,
direct comparative randomized trials (and meta-
analyses of these direct comparisons) constitute
the highest level of evidence to guide our patient
care. Where direct comparative randomized trials
exist, their role cannot be supplanted by indirect
comparison network meta-analyses irrespective
of how sophisticated they are. Speciﬁcally, 2 ran-
domized trials of BP-DES versus EES (4,5) are the
only relevant direct comparison trials included in
the 2 network meta-analyses quoted by Dr. Philip.
Neither trial showed differences between BP-DES
and EES regarding both stent thrombosis and
myocardial infarction (p $0.18). A simple pooling
together of these 2 studies, which enrolled a total of
5,942 patients, will yield a 1-year incidence of
myocardial infarction of 3.0% in the BP-DES group
and 2.9% in the EES group as well as an incidence of
deﬁnite and probable stent thrombosis of 0.5% in
the BP-DES group and 0.4% in the EES group (4,5).
Thus, the direct comparison randomized trials do
not support the existence of a signiﬁcant safety
disadvantage of BP-DES versus EES. Finally,
awareness of an excess thrombotic risk with a
certain DES among the multitude of DES that are
currently available should reasonably lead to the
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